Xintela AB (publ) (STO:XINT)
Sweden · Delayed Price · Currency is SEK 0.2720
-0.0100 (-3.55%)
At close: Feb 26, 2026
Xintela AB Market Cap
Xintela AB has a market cap or net worth of 242.88 million as of February 26, 2026. Its market cap has increased by 3.15% in one year.
Market Cap
242.88M
Enterprise Value
239.50M
Revenue
2.96M
Ranking
n/a
PE Ratio
n/a
Stock Price
0.27
Market Cap Chart
Since March 22, 2016, Xintela AB's market cap has increased from 103.68M to 242.88M, an increase of 134.26%. That is a compound annual growth rate of 8.94%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 25, 2026 | 242.88M | 22.25% |
| Dec 30, 2025 | 198.68M | 5.85% |
| Dec 30, 2024 | 187.69M | 26.87% |
| Dec 29, 2023 | 147.94M | -1.74% |
| Dec 30, 2022 | 150.56M | -26.24% |
| Dec 30, 2021 | 204.12M | 2.23% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Mar 22, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Elicera Therapeutics AB | 304.32M |
| Lipum AB | 295.91M |
| Bio-Works Technologies AB | 294.30M |
| Mendus AB | 293.55M |
| AlzeCure Pharma AB | 233.28M |
| Sprint Bioscience AB | 230.02M |
| Isofol Medical AB | 227.13M |
| Initiator Pharma | 225.21M |